Phase II single-arm trial of safety, antitumor activity, and pharmacokinetics of tusamitamab ravtansine (SAR408701) plus ramucirumab in CEACAM5-positive, metastatic, non-squamous, non-small cell lung cancer progressing on platinum-based chemotherapy and immunotherapy

被引：2
|
作者：
Cho, B. C. [1 ]
Aguado de la Rosa, C. [2 ]
Vila, L. [3 ]
Isla, D. [4 ]
Oliveira, J. [5 ]
de Castro Carpeno, J. [6 ]
Tomova, A. [7 ]
Kim, T. M. [8 ]
Blasco Cordellat, A. [9 ]
Bauchet, A-L. [10 ]
Soufflet, C. [11 ]
Bensfia, S. [12 ]
Dy, G. [13 ]
机构：
[1] Yonsei Univ, Yonsei Canc Ctr, Coll Med, Seoul, South Korea
[2] Hosp Clin San Carlos, Madrid, Spain
[3] Parc Tauli Hosp Univ, Barcelona, Spain
[4] Hosp Clin Lozano Blesa, Zaragoza, Spain
[5] Inst Portugues Oncol Porto Francisco Gentil EPE, Porto, Portugal
[6] Hosp Univ La Paz, Madrid, Spain
[7] Complex Oncol Ctr Plovdiv, Plovdiv, Bulgaria
[8] Seoul Natl Univ Hosp, Seoul, South Korea
[9] Hosp Univ Valencia, Valencia, Spain
[10] Sanofi, Chilly Mazarin, France
[11] Sanofi, Boulogne, France
[12] Sanofi, Cambridge, MA USA
[13] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1965
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1364TiP
引用
收藏
页码：S1034 / S1035
页数：2
相关论文
共 50 条
  • [21] A PHASE III TRIAL OF RH-ENDOSTATIN PLUS PLATINUM-BASED CHEMOTHERAPY VERSUS PLATINUM-BASED CHEMOTHERAPY IN PREVIOUSLY UNTREATED NON-SMALL CELL LUNG CANCER PATIENTS
    Zhou, J.
    Xiang, Y.
    Gao, B.
    Chen, W.
    Li, Q.
    Wan, H.
    RESPIROLOGY, 2011, 16 : 147 - 147
  • [22] Pharmacological ascorbate enhances platinum-based chemotherapy responses in metastatic non-small cell lung cancer (NSCLC): A phase II clinical trial.
    Furqan, Muhammad
    Abu-Hejleh, Taher
    Bodeker, Kellie L.
    Pietrok, Laura M.
    Hartwig, Stacey M.
    Tremblay, Mikaela M.
    Fosdick, Micaela G.
    Houtman, Jon
    Varga, Steven
    Pulliam, Casey F.
    Petronek, Michael
    Fath, Melissa A.
    Mott, Sarah L.
    Bossler, Aaron D.
    Bellizzi, Andrew M.
    Zhang, Jun
    Mani, Hariharasudan
    Monga, Varun
    Smith, Brian J.
    Cullen, Joseph
    Wagner, Brett A.
    Buettner, Garry R.
    Buatti, John M.
    Spitz, Douglas R.
    Allen, Bryan G.
    CANCER RESEARCH, 2021, 81 (13)
  • [23] A multicenter phase II study of S-1 combined with bevacizumab after platinum-based chemotherapy in patients with advanced non-squamous non-small cell lung cancer.
    Tokito, Takaaki
    Yamada, Kazuhiko
    Ichiki, Masao
    Takahashi, Kazuhisa
    Hisamatsu, Yasushi
    Azuma, Koichi
    Ishii, Hidenobu
    Shukuya, Takehito
    Takeoka, Hiroaki
    Nishikawa, Kazuo
    Hoshino, Tomoaki
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [24] A phase II trial of induction of erlotinib followed by cytotoxic chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer patients
    Tetsuo Tani
    Katsuhiko Naoki
    Hiroyuki Yasuda
    Daisuke Arai
    Kota Ishioka
    Keiko Ohgino
    Satoshi Yoda
    Sohei Nakayama
    Ryosuke Satomi
    Hideki Terai
    Shinnosuke Ikemura
    Takashi Sato
    Kenzo Soejima
    Cancer Chemotherapy and Pharmacology, 2019, 84 : 1065 - 1071
  • [25] A phase II trial of induction of erlotinib followed by cytotoxic chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer patients
    Tani, Tetsuo
    Naoki, Katsuhiko
    Yasuda, Hiroyuki
    Arai, Daisuke
    Ishioka, Kota
    Ohgino, Keiko
    Yoda, Satoshi
    Nakayama, Sohei
    Satomi, Ryosuke
    Terai, Hideki
    Ikemura, Shinnosuke
    Sato, Takashi
    Soejima, Kenzo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (05) : 1065 - 1071
  • [26] Efficacy and safety of second-line therapy of docetaxel plus ramucirumab after first-line platinum-based chemotherapy plus immune checkpoint inhibitors in non-small cell lung cancer (SCORPION): a multicenter, open-label, single-arm, phase 2 trial
    Matsuzawa, Reiko
    Morise, Masahiro
    Ito, Kentaro
    Hataji, Osamu
    Takahashi, Kosuke
    Koyama, Junji
    Kuwatsuka, Yachiyo
    Imaizumi, Kazuyoshi
    Goto, Yasuhiro
    Itani, Hidetoshi
    Yamaguchi, Teppei
    Zenke, Yoshitaka
    Oki, Masahide
    Ishii, Makoto
    ECLINICALMEDICINE, 2023, 66
  • [27] Neoadjuvant toripalimab plus chemotherapy in patients with potentially resectable non-small cell lung cancer: A prospective, single-arm, phase II trial (Renaissance Study)
    Yan, S.
    Chen, J.
    Wang, J.
    Lv, C.
    Bi, J.
    Yang, X.
    Li, S.
    Wang, Y.
    Li, X.
    Yang, Y.
    Wu, N.
    ANNALS OF ONCOLOGY, 2021, 32 : S1400 - S1400
  • [28] A phase II randomized trial evaluating gefitinib intercalated with pemetrexed/platinum chemotherapy or pemetrexed/platinum chemotherapy alone in unselected patients with advanced non-squamous non-small cell lung cancer
    Yu, Hui
    Zhang, Jian
    Wu, Xianghua
    Luo, Zhiguo
    Wang, Huijie
    Sun, Si
    Peng, Wei
    Qiao, Jie
    Feng, Yu
    Wang, Jialei
    Chang, Jianhua
    CANCER BIOLOGY & THERAPY, 2014, 15 (07) : 832 - 839
  • [29] Docetaxel and cyclooxygenase-2 inhibition with celecoxib for advanced non-small cell lung cancer progressing after platinum-based chemotherapy: a multicenter phase II trial
    Nugent, FW
    Mertens, WC
    Graziano, S
    Levitan, N
    Collea, R
    Gajra, A
    Marshall, J
    McCann, J
    LUNG CANCER, 2005, 48 (02) : 267 - 273
  • [30] Anlotinib in Chinese patients aged ≥70 years with advanced non-squamous non-small cell lung cancer without prior chemotherapy: a multicenter, single-arm pilot trial
    Zhao, Da
    Li, Zhengguo
    Hou, Xinli
    Yang, Lei
    Li, Zeng
    Yan, Li
    Li, Hongling
    Liu, Hua
    Liu, Xiaoping
    Song, Feixue
    Li, Guixiang
    Zhang, Yu
    Hou, Xiaoming
    FRONTIERS IN ONCOLOGY, 2024, 14
12345